ZCCHC11 Antibody

What is ZCCHC11 and what are its key cellular functions?

ZCCHC11, also known as TUT4 or PAPD3, is a ribonucleotidyltransferase that plays critical roles in post-transcriptional regulation of gene expression. The protein contains RNA-interacting motifs and functions primarily as an uridylyltransferase that mediates terminal uridylation of specific microRNAs . In cellular processes, ZCCHC11 serves as a key regulator of cytokine expression by modifying microRNAs that target cytokine transcripts, particularly interleukin-6 (IL-6) .

The protein has significant functions in maintaining embryonic stem cell pluripotency through its activity in degrading pre-let-7 miRNAs. Specifically, ZCCHC11 catalyzes the 3' uridylation of precursor let-7, which prevents processing by Dicer and targets these miRNAs for degradation . This mechanism is essential for maintaining the pluripotent state of embryonic stem cells. Additionally, ZCCHC11 has been implicated in suppressing Toll-like receptor-induced NF-kappa-B activity through its interaction with T2BP .

What is the molecular mechanism by which ZCCHC11 regulates cytokine expression?

ZCCHC11 regulates cytokine expression through a sophisticated post-transcriptional mechanism involving microRNA modification. The protein functions as a ribonucleotidyltransferase with a preference for uridine nucleotides . This enzymatic activity is critical for maintaining the poly(A) tail length and stability of transcripts for interleukin-6 (IL-6) and select other cytokines .

The molecular pathway involves the mir-26 family of miRNAs that normally target and repress IL-6 transcripts. ZCCHC11 catalyzes the addition of terminal uridines to the 3' end of mir-26a, which abrogates its repressive function on IL-6 . Research has demonstrated that in control cells, approximately 78% of mir-26a sequences contain 1-3 uridines on their 3' ends, whereas in Zcchc11 knock-down cells, less than 0.1% retained these uridine modifications . This uridylation mechanism represents an enzymatic modification of mature miRNA as a novel means for regulating gene expression and fine-tuning cytokine production.

What is the tissue distribution profile of ZCCHC11 protein?

While ZCCHC11 mRNA appears to be ubiquitously expressed across mouse tissues, the protein expression follows a more tissue-specific distribution pattern . According to research findings, ZCCHC11 protein is most prominently expressed in the thymus, spleen, testes, and lung . This tissue-specific expression pattern suggests specialized roles in immune function and mucosal defense.

In addition to tissue expression, ZCCHC11 has been detected in both human and mouse lung alveolar epithelial cell lines (A549 and MLE-15, respectively) . The preferential expression in immune and mucosal tissues further supports ZCCHC11's significant role in cytokine regulation, which is critical for coordinating immune responses and maintaining tissue homeostasis in these organs.

What are the recommended applications for ZCCHC11 antibodies?

ZCCHC11 antibodies have been validated for multiple research applications across different experimental platforms. Based on technical specifications from manufacturers, these antibodies can be reliably used for Western blotting (WB), immunocytochemistry (ICC), immunofluorescence (IF), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA) . Additionally, some ZCCHC11 antibodies have been validated for immunohistochemistry (IHC) applications with recommended dilutions of 1:50 to 1:200 .

For optimal results in each application, researchers should follow manufacturer-specific protocols. For instance, in immunohistochemistry applications, proper antigen retrieval techniques are essential, and dilution optimization may be required depending on the specific tissue being analyzed. When using ZCCHC11 antibodies for Western blotting, researchers should note the calculated molecular weight of the protein (approximately 185.166 kDa) to correctly identify the target band .

How should researchers interpret changes in cytokine profiles after ZCCHC11 knockdown?

Interpreting cytokine profile changes following ZCCHC11 knockdown requires careful analysis as the protein affects multiple cytokines differentially. Research demonstrates that ZCCHC11 depletion using siRNA results in a complex pattern of cytokine expression changes. Specifically, IL-6, VEGF, TGF-α, and RANTES production significantly decreases, while other cytokines such as fractalkine, IP-10, MCP-1, G-CSF, and GM-CSF remain largely unaffected . Interestingly, IL-8 concentrations actually increase following ZCCHC11 knockdown .

When designing experiments to study ZCCHC11's role in cytokine regulation, researchers should implement time-course analyses, as the impact of ZCCHC11 knockdown on IL-6 expression becomes more pronounced over time . Additionally, it's crucial to verify the effectiveness of ZCCHC11 knockdown through methods such as immunoblotting before attributing cytokine changes to ZCCHC11 depletion. The cytokine-specific effects should be validated across multiple cell lines and with different stimulation conditions, as these effects have been consistent across human A549 cells, HEK 293T cells, and murine MLE-15 cells, and with different stimuli including TNF-α and Escherichia coli .

What techniques are recommended for analyzing ZCCHC11-mediated miRNA modifications?

Analyzing ZCCHC11-mediated miRNA modifications requires specialized techniques that can detect nucleotide additions at the 3' end of microRNAs. The most effective approach combines deep sequencing of small RNAs with careful bioinformatic analysis to quantify uridylation patterns . When examining miRNA modifications, researchers should first isolate small RNA fractions using optimized extraction protocols that preserve the 3' end integrity of miRNAs.

Complementary approaches may include northern blotting with probes specific for particular miRNAs, which can detect size shifts associated with uridylation, or specialized PCR-based methods designed to amplify and distinguish between modified and unmodified miRNA species.

What controls should be included when validating ZCCHC11 antibody specificity?

Validating ZCCHC11 antibody specificity requires multiple controls to ensure reliable and reproducible results. First, researchers should include a knockout or knockdown control where ZCCHC11 expression is depleted using siRNA or CRISPR-Cas9 technology . This allows confirmation that the detected signal truly corresponds to ZCCHC11 and not to non-specific binding.

For Western blotting applications, researchers should verify that the detected band appears at the expected molecular weight of approximately 185.166 kDa . Additionally, multiple tissue samples should be tested to confirm the known tissue-specific expression pattern, with strongest signals expected in thymus, spleen, testes, and lung tissues .

When validating antibodies for immunoprecipitation experiments, researchers should perform reciprocal co-immunoprecipitation with antibodies against known ZCCHC11 interacting partners such as LIN28 and LIN28B . For immunohistochemistry and immunofluorescence applications, peptide competition assays can be performed, where the antibody is pre-incubated with the immunogen peptide, which should abolish specific staining.

Finally, researchers should consider using multiple antibodies raised against different epitopes of ZCCHC11 to confirm consistent detection patterns, especially when investigating previously uncharacterized aspects of ZCCHC11 biology.

How can researchers differentiate between ZCCHC11/TUT4 and other terminal uridylyltransferases in functional studies?

Differentiating between ZCCHC11/TUT4 and other terminal uridylyltransferases (TUTases) in functional studies requires a multi-faceted approach that examines substrate specificity, interacting partners, and cellular context. ZCCHC11 has a preference for specific miRNA substrates, particularly the mir-26 family and pre-let-7 miRNAs . Researchers can exploit these substrate preferences by conducting targeted analyses of these specific miRNAs when attempting to attribute functional effects to ZCCHC11.

A key distinguishing feature of ZCCHC11 is its dependency on protein partners for RNA binding. Unlike some other TUTases, ZCCHC11 cannot bind RNA by itself but requires recruitment to its targets via interaction with proteins such as LIN28 and LIN28B in the case of pre-let-7 miRNAs . Co-immunoprecipitation experiments that identify these specific protein interactions can help differentiate ZCCHC11 activity from other TUTases.

Selective knockdown strategies are also crucial for distinguishing between different TUTases. When designing siRNA or shRNA constructs targeting ZCCHC11, researchers must verify specificity by showing that expression of other TUTases remains unchanged. Similarly, rescue experiments using expression constructs for wild-type ZCCHC11 versus catalytically inactive mutants can confirm that observed effects are due to ZCCHC11's enzymatic activity rather than structural roles.

What are the implications of ZCCHC11's role in embryonic stem cell biology?

ZCCHC11's role in embryonic stem cell biology centers on its regulation of the let-7 family of microRNAs, which are critical determinants of cellular differentiation and development. By catalyzing the 3' uridylation of precursor let-7 (pre-let-7) miRNAs, ZCCHC11 prevents their processing by Dicer, leading to their degradation . This mechanism actively suppresses the maturation of let-7 miRNAs, which would otherwise promote differentiation.

This function has profound implications for stem cell research. First, it suggests that modulating ZCCHC11 activity could provide a means to control stem cell fate decisions. Inhibiting ZCCHC11 might accelerate differentiation by allowing let-7 accumulation, while enhancing its activity could help maintain pluripotency. Researchers studying induced pluripotent stem cells (iPSCs) should consider investigating ZCCHC11 as a potential factor in reprogramming protocols.

The stem cell-specific role of ZCCHC11 also suggests it may function differently in progenitor cells versus terminally differentiated cells, which has implications for developmental biology research. Temporal regulation of ZCCHC11 during development might mark critical windows for cell fate decisions, making it a potentially valuable marker for specific developmental stages.

Finally, given its role in maintaining pluripotency, aberrant expression or activity of ZCCHC11 in adult tissues might contribute to dysregulated cell growth or cancer development, suggesting potential applications in cancer research and regenerative medicine.

What are the optimal storage and handling conditions for ZCCHC11 antibodies?

ZCCHC11 antibodies require specific storage and handling conditions to maintain their functionality and specificity. For long-term storage, manufacturers recommend keeping antibodies at -20°C . Most commercial ZCCHC11 antibodies are supplied in a buffered aqueous glycerol solution, which helps prevent freeze-thaw damage .

When working with these antibodies, researchers should aliquot the stock solution upon first thawing to minimize freeze-thaw cycles, as repeated freezing and thawing can significantly reduce antibody activity and specificity. For working solutions, antibodies can typically be stored at 2-8°C for up to six months after reconstitution .

Before each use, antibodies should be gently mixed (not vortexed) to ensure homogeneity without damaging the protein structure. When diluting antibodies for specific applications, use high-quality, fresh buffers that are appropriate for the intended application. For Western blotting, a common dilution buffer contains PBS with a small percentage of non-fat dry milk or BSA and a mild detergent like Tween-20.

If decreased performance is observed over time, researchers should consider potential contamination or degradation issues and obtain a fresh lot of antibody if necessary.

How should researchers optimize ZCCHC11 antibody concentrations for different applications?

Optimizing ZCCHC11 antibody concentrations for different applications requires systematic titration experiments and consideration of specific experimental conditions. For immunohistochemistry applications, manufacturers recommend starting with dilutions between 1:50 and 1:200 , but optimal concentrations may vary depending on tissue type, fixation method, and detection system.

For Western blotting, researchers should begin with the manufacturer's recommended dilution and then perform a dilution series to determine the optimal antibody concentration that maximizes specific signal while minimizing background. Critical factors to consider include protein loading amount, transfer efficiency, blocking conditions, and incubation times and temperatures.

For immunoprecipitation experiments, higher concentrations of antibody are typically required, and researchers should determine the minimum amount needed to efficiently pull down ZCCHC11 through pilot experiments. For co-immunoprecipitation studies investigating ZCCHC11's interactions with partners like LIN28, optimization should include varying antibody-to-bead ratios and wash stringencies.

When using ZCCHC11 antibodies for immunofluorescence or immunocytochemistry, researchers should systematically test different fixation methods, permeabilization conditions, and antibody concentrations. Comparing results with known ZCCHC11 expression patterns can help confirm optimal conditions.

In all applications, inclusion of positive controls (tissues known to express high levels of ZCCHC11 such as thymus, spleen, testes, and lung) and negative controls (including secondary antibody only) is essential for accurate optimization.

What troubleshooting approaches are recommended when ZCCHC11 antibodies show unexpected results?

When encountering unexpected results with ZCCHC11 antibodies, researchers should implement a systematic troubleshooting approach. First, verify the antibody's integrity by checking expiration date, storage conditions, and appearance for signs of contamination or precipitation. If the antibody has undergone multiple freeze-thaw cycles, protein degradation may have occurred, necessitating a fresh aliquot.

For Western blotting issues, consider the following approaches:

• If no signal is detected, verify transfer efficiency using a reversible protein stain on the membrane

• If multiple bands appear, increase washing stringency and optimize blocking conditions

• For high background, dilute the antibody further and ensure thorough washing

• If the band appears at an unexpected molecular weight, verify sample preparation and consider post-translational modifications or proteolytic processing

For immunohistochemistry or immunofluorescence applications with non-specific staining, optimize antigen retrieval methods, reduce antibody concentration, and try different blocking reagents. If the expected tissue distribution pattern (strongest in thymus, spleen, testes, and lung) is not observed, consider tissue fixation variables and antigen masking issues .

If ZCCHC11 knockdown controls do not show reduced signal, verify knockdown efficiency at both mRNA and protein levels using RT-PCR and Western blotting respectively . Consider the half-life of ZCCHC11 protein when designing knockdown experiments, as stable proteins may require longer periods after siRNA treatment before significant depletion is observed.

How can ZCCHC11 antibodies be used to study cytokine regulation in inflammatory diseases?

ZCCHC11 antibodies provide valuable tools for investigating cytokine dysregulation in inflammatory diseases, given ZCCHC11's established role in regulating IL-6 and other pro-inflammatory mediators . Researchers can employ these antibodies to assess ZCCHC11 expression levels in patient samples and animal models of inflammatory conditions, potentially identifying correlations between ZCCHC11 expression and disease severity or progression.

Immunohistochemistry with ZCCHC11 antibodies can reveal tissue-specific expression patterns in inflammatory lesions, while co-localization studies using dual immunofluorescence can examine the relationship between ZCCHC11 and its target cytokines or regulatory miRNAs in affected tissues. These approaches can help elucidate whether ZCCHC11 dysregulation contributes to pathological inflammatory responses.

For mechanistic studies, researchers can combine ZCCHC11 antibodies with specific cytokine ELISAs following ZCCHC11 modulation to establish causal relationships. Additionally, chromatin immunoprecipitation (ChIP) experiments using antibodies against transcription factors involved in cytokine regulation, coupled with ZCCHC11 knockdown or overexpression, can help delineate the interplay between transcriptional and post-transcriptional regulatory mechanisms.

Given ZCCHC11's role in uridylating miR-26a and thereby regulating IL-6 expression , researchers might explore therapeutic strategies targeting this pathway in inflammatory diseases characterized by IL-6 dysregulation, such as rheumatoid arthritis or inflammatory bowel disease.

What considerations are important when designing experiments to study ZCCHC11's role in stem cell biology?

Designing experiments to study ZCCHC11's role in stem cell biology requires careful consideration of multiple factors given its critical function in maintaining pluripotency through pre-let-7 miRNA uridylation . Researchers should begin by characterizing ZCCHC11 expression and activity throughout differentiation processes, using both antibody-based detection methods and functional assays for uridyltransferase activity.

When modulating ZCCHC11 expression in stem cells, researchers must consider the timing of intervention, as its importance may vary at different stages of differentiation. Inducible knockdown or overexpression systems allow for temporal control and can help identify critical windows during which ZCCHC11 activity influences cell fate decisions.

Since ZCCHC11 functions in complex with LIN28 and LIN28B to regulate pre-let-7 miRNAs , experimental designs should account for this interaction. Co-immunoprecipitation experiments using ZCCHC11 antibodies can confirm the presence and composition of these regulatory complexes in different stem cell populations. Additionally, mutations that disrupt specific protein-protein interactions can help distinguish between ZCCHC11's enzymatic activity and its structural roles within larger complexes.

For comprehensive analysis, researchers should monitor multiple pluripotency markers alongside let-7 miRNA levels and their targets when manipulating ZCCHC11 expression. Single-cell analyses may be particularly valuable to capture heterogeneity in stem cell populations and identify subpopulations with differential dependence on ZCCHC11 activity.

How might advances in ZCCHC11 research influence therapeutic development for miRNA-related disorders?

Advances in ZCCHC11 research have significant implications for therapeutic development targeting miRNA-related disorders. ZCCHC11's role as a post-transcriptional regulator of miRNA function through uridylation represents a novel mechanism that could be exploited pharmacologically . Small molecule inhibitors of ZCCHC11's catalytic activity could potentially modulate specific miRNA functions without directly targeting the miRNAs themselves, offering a more selective approach than current miRNA-based therapeutics.

In inflammatory conditions characterized by excessive cytokine production, inhibiting ZCCHC11 could enhance the repressive function of miR-26a on IL-6 transcripts, potentially reducing inflammatory responses . Conversely, in contexts where increased cytokine production is beneficial, such as certain immunodeficiencies or vaccination responses, enhancing ZCCHC11 activity might boost protective immunity.

For stem cell-based therapies, modulating ZCCHC11 activity could help optimize protocols for maintaining pluripotency or directing differentiation . Temporary inhibition of ZCCHC11 during specific stages of induced pluripotent stem cell (iPSC) generation or differentiation might improve efficiency and specificity of resulting cell populations.

Future therapeutic approaches might also target specific ZCCHC11 interactions, such as its binding to LIN28/LIN28B, rather than its catalytic activity . This strategy could provide context-specific modulation of ZCCHC11 function, potentially reducing off-target effects associated with complete inhibition of its enzymatic activity.